CN109170916A - 一种强身健体食品组合物及其制备方法 - Google Patents
一种强身健体食品组合物及其制备方法 Download PDFInfo
- Publication number
- CN109170916A CN109170916A CN201811299271.6A CN201811299271A CN109170916A CN 109170916 A CN109170916 A CN 109170916A CN 201811299271 A CN201811299271 A CN 201811299271A CN 109170916 A CN109170916 A CN 109170916A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- weight
- healthy
- food compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 235000001497 healthy food Nutrition 0.000 title abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 114
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 58
- 235000013305 food Nutrition 0.000 claims abstract description 41
- 239000005018 casein Substances 0.000 claims abstract description 33
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000021240 caseins Nutrition 0.000 claims abstract description 33
- 102000008186 Collagen Human genes 0.000 claims abstract description 32
- 108010035532 Collagen Proteins 0.000 claims abstract description 32
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 32
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 32
- 229920001436 collagen Polymers 0.000 claims abstract description 32
- 230000007062 hydrolysis Effects 0.000 claims abstract description 31
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 241000251468 Actinopterygii Species 0.000 claims abstract description 27
- 229940106134 krill oil Drugs 0.000 claims abstract description 26
- 235000013336 milk Nutrition 0.000 claims abstract description 23
- 239000008267 milk Substances 0.000 claims abstract description 23
- 210000004080 milk Anatomy 0.000 claims abstract description 23
- 102000002322 Egg Proteins Human genes 0.000 claims abstract 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 29
- 241000251511 Holothuroidea Species 0.000 claims description 29
- 239000011575 calcium Substances 0.000 claims description 29
- 229910052791 calcium Inorganic materials 0.000 claims description 29
- 210000002969 egg yolk Anatomy 0.000 claims description 28
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 26
- 235000020243 first infant milk formula Nutrition 0.000 claims description 22
- 244000197580 Poria cocos Species 0.000 claims description 19
- 235000008599 Poria cocos Nutrition 0.000 claims description 19
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 18
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 18
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 18
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 18
- 241001558017 Gynura Species 0.000 claims description 18
- 244000046146 Pueraria lobata Species 0.000 claims description 18
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 18
- 235000001122 chang geng bian tao Nutrition 0.000 claims description 18
- 235000019198 oils Nutrition 0.000 claims description 18
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 18
- 235000008708 Morus alba Nutrition 0.000 claims description 17
- 244000237330 gutta percha tree Species 0.000 claims description 17
- 244000068988 Glycine max Species 0.000 claims description 16
- 235000010469 Glycine max Nutrition 0.000 claims description 16
- 240000007049 Juglans regia Species 0.000 claims description 16
- 235000009496 Juglans regia Nutrition 0.000 claims description 16
- 241000218231 Moraceae Species 0.000 claims description 16
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 16
- 235000020234 walnut Nutrition 0.000 claims description 16
- 241000233866 Fungi Species 0.000 claims description 15
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 13
- 239000012535 impurity Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 235000014036 Castanea Nutrition 0.000 claims description 11
- 241001070941 Castanea Species 0.000 claims description 11
- 238000010411 cooking Methods 0.000 claims description 6
- 235000006667 Aleurites moluccana Nutrition 0.000 claims description 5
- 235000018244 Castanea mollissima Nutrition 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims description 5
- 235000013601 eggs Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 3
- 108010000912 Egg Proteins Proteins 0.000 claims 3
- 235000014103 egg white Nutrition 0.000 claims 3
- 210000000969 egg white Anatomy 0.000 claims 3
- 244000136475 Aleurites moluccana Species 0.000 claims 1
- 241000219780 Pueraria Species 0.000 claims 1
- 244000285940 beete Species 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 235000011222 chang cao shi Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 208000001132 Osteoporosis Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000003712 anti-aging effect Effects 0.000 abstract description 8
- 230000003349 osteoarthritic effect Effects 0.000 abstract description 7
- 230000001151 other effect Effects 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 5
- 230000000052 comparative effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 230000037182 bone density Effects 0.000 description 16
- 239000003921 oil Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241000207961 Sesamum Species 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 201000008482 osteoarthritis Diseases 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 240000004957 Castanea mollissima Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 244000144993 groups of animals Species 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009758 senescence Effects 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229920002567 Chondroitin Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 108010048734 sclerotin Proteins 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 240000002624 Mespilus germanica Species 0.000 description 2
- 235000017784 Mespilus germanica Nutrition 0.000 description 2
- 235000000560 Mimusops elengi Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 235000007837 Vangueria infausta Nutrition 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003262 anti-osteoporosis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000005195 poor health Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000219112 Cucumis Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 241000195620 Euglena Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000008845 cholagoga Substances 0.000 description 1
- 229940124571 cholagogue Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002391 femur head Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- KFZAUHNPPZCSCR-UHFFFAOYSA-N iron zinc Chemical compound [Fe].[Zn] KFZAUHNPPZCSCR-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000029761 vertebral disease Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- -1 zinc rich in Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
- A23L13/60—Comminuted or emulsified meat products, e.g. sausages; Reformed meat from comminuted meat product
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/70—Comminuted, e.g. emulsified, fish products; Processed products therefrom such as pastes, reformed or compressed products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供了一种强身健体食品组合物及其制备方法,该组合物包括以下重量份的各组分:酪蛋白磷酸肽0.001‑0.3份、深海鱼胶原蛋白肽0.05‑3份、牦牛骨粉0.01‑2份、初乳碱性蛋白0.005‑1份、水解蛋黄粉0.01‑2份、磷虾油粉0.001‑0.2份,可用于制备保健食品,该保健食品组合物能够预防和改善骨关节炎症、骨质疏松症等骨骼疾病,同时具有延缓衰老、预防老年疾病、强身健体等功效,适合长期服用。
Description
技术领域
本发明涉及保健品技术领域,具体涉及一种强身健体食品组合物及其制备方法。
背景技术
近年来人们对骨骼的健康越来越关注,常见的骨骼疾病包括:骨质疏松、各类关节炎、骨质增生、骨膜炎、颈椎病、腰椎病、肩周炎、股骨头坏死等,严重的会引起骨折、关节变形、丧失关节功能,导致残疾、瘫痪等严重后果,让人们的身心深受折磨。随着老龄化程度的加剧,这些骨骼疾病一般常见于中老年人、绝经后的女性、低体重的瘦小者、日常缺少运动的人、长期使用激素者,其中过度吸烟饮酒者骨质疏松年龄明显提前。目前,全世界骨关节炎患者有3.6亿人,而我国的40岁以上的骨质疏松患者达1.12亿人。可见要预防和改善骨关节炎、骨质疏松等骨骼疾病尤为重要,最科学的方法就是在补充钙的同时加强人体对钙的吸收利用能力。
酪蛋白磷酸肽(即CPP)是以牛乳酪蛋白为原料,经水解、分离纯化得到的一类富含磷酸丝氨酸的生物活性肽,不仅能够促进人体对钙的吸收利用,还促进铁、锌、硒等离子的吸收,被誉为“矿物质载体”。人体骨组织由1/3有机物及2/3无机物构成,胶原蛋白占有机成分80%-90%,胶原蛋白是骨骼健康的关键,胶原蛋白不仅仅提高骨骼韧性还起到黏附钙的重要作用,也就起到了提高骨密度的效果。深海鱼胶原蛋白肽是以鱼鳞或鱼皮等为原料,经酶解、分离、精制和干燥等加工过程而制得的小分子低聚肽,摄食胶原蛋白肽可增强低钙水平下的骨胶原结构,从而提高了骨强度,即达到预防骨质疏松症作用,还可作新陈代谢促进剂使用,改善随年龄增长导致的生物组织衰老和功能减退。另外,牦牛骨粉富含骨胶原蛋白、骨形成蛋白、软骨素及钙、磷、铁锌等营养成分,对增强人体骨密度,修复骨密度也有很好的效果。初乳碱性蛋白、水解蛋黄粉、磷虾油粉、长柄扁桃油等物质对骨关节炎、骨质疏松骨骼疾病等同样具有良好的效果,能够促进钙的吸收,同时抑制钙的过度流失。
目前,中国专利公布CN108402460A公开了一种增加骨密度的多功能食品组合物及其制备方法,该组合物含有葛根、枸杞子、黄精、山药、大枣、牡蛎、阿胶、玉竹、茯苓、甘份、木瓜、薏苡仁,具有增加骨密度、辅助降血脂、辅助改善记忆、护肝利胆的功能。中国专利公布CN107252099A公开了一种改善骨关节炎症的保健食品及其制备方法,该组合物含有水解蛋黄粉、橄榄汁冻干粉、钙剂、松花粉肽、玛咖肽、裸藻肽、微晶纤维素、白砂糖和硬脂酸镁,能够改善骨关节损伤,消除细胞炎症,但其功效单一,且制备方法较为复杂。
在骨关节炎、骨质疏松等中老年疾病中,常伴有高血压、高血糖、高血脂、老年痴呆、心脑血管疾病等一些老年性疾病。因此,将多种良好的钙补充物质与具有延缓衰老、健脑、防止人体动脉硬化、骨骼关节硬化、促进新陈代谢等功效的药材和食品相结合,组成的组合物是一种有效的强身健体的保健品。
发明内容
本发明提供了一种强身健体食品组合物及其制备方法,该组合物适用于中老年人,在预防和改善骨关节炎、骨质疏松的同时,也具有延缓衰老、健脑、预防老年疾病、强身健体等功效。
本发明一方面提供了一种强身健体食品组合物,按重量份数计包括以下组分:酪蛋白磷酸肽0.001-0.3份、深海鱼胶原蛋白肽0.05-3份、牦牛骨粉0.01-2份、初乳碱性蛋白0.005-1份、水解蛋黄粉0.01-2份、磷虾油粉0.001-0.2份。
优选地,所述的强身健体食品组合物,按重量份数计包括以下组分:酪蛋白磷酸肽0.01-0.3份、深海鱼胶原蛋白肽0.05-2份、牦牛骨粉0.01-1份、初乳碱性蛋白0.005-0.5份、水解蛋黄粉0.01-1份、磷虾油粉0.01-0.2份。
所述的强身健体食品组合物,按重量份计还含有海参0.01-1份、长柄扁桃油0.001-1份、杜仲籽油0.001-0.5份、白子菜0.1-3份、茯苓0.5-3份、葛根0.1-3份、枸杞子0.1-2份。
所述的强身健体食品组合物,按重量份计还含有桑葚0.05-2份、核桃仁0.1-3份、芝麻0.01-2份、山药0.1-2份、栗子0.01-2份、大豆0.5-3份、黑木耳0.1-2份。
所述的强身健体食品组合物,按重量份计还含有碳酸钙0.01-2份、奶粉0.01-2份。
所述的强身健体食品组合物,按重量份数计包括以下组分:酪蛋白磷酸肽0.01-0.3份、深海鱼胶原蛋白肽0.05-2份、牦牛骨粉0.01-1份、初乳碱性蛋白0.005-0.5份、水解蛋黄粉0.01-1份、磷虾油粉0.01-0.2份、海参0.01-1份、长柄扁桃油0.001-0.1份、杜仲籽油0.005-0.1份、白子菜0.1-3份、茯苓0.5-3份、葛根0.1-3份、枸杞子0.1-2份、桑葚0.05-2份、核桃仁0.1-3份、芝麻0.01-2份、山药0.1-2份、栗子0.01-2份、大豆0.5-3份、黑木耳0.1-2份、碳酸钙0.1-2份、奶粉0.05-2份、复合维生素0.01-1份、复合矿物质0.01-1份。
优选地,所述的强身健体食品组合物,按重量份数计包括以下组分:酪蛋白磷酸肽0.01-0.1份、深海鱼胶原蛋白肽0.1-1.5份、牦牛骨粉0.1-1份、初乳碱性蛋白0.01-0.5份、水解蛋黄粉0.1-1份、磷虾油粉0.01-0.1份、海参0.01-0.5份、长柄扁桃油0.005-0.05份、杜仲籽油0.01-0.1份、白子菜0.5-2份、茯苓0.5-2份、葛根0.1-1.5份、枸杞子0.1-1.5份、桑葚0.1-2份、核桃仁0.5-2份、芝麻0.1-1.5份、山药0.5-1.5份、栗子0.1-1.5份、大豆0.5-5份、黑木耳0.1-1.5份、碳酸钙0.1-1份、奶粉0.1-2份、复合维生素0.05-0.5份、复合矿物质0.01-0.5份。
所述的强身健体食品组合物中,酪蛋白磷酸肽和初乳碱性蛋白的重量比为0.1-10:1;牦牛骨粉和水解蛋黄粉的重量比为0.01-2:1。
优选地,所述的强身健体食品组合物中,酪蛋白磷酸肽和初乳碱性蛋白的重量比为0.1-2:1;牦牛骨粉和水解蛋黄粉的重量比为0.01-1:1。
本发明另一方面提供了一种强身健体食品组合物的制备方法,包括以下步骤:
(1)按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉和碳酸钙混合均匀,得到混合物A;
(2)按重量份取白子菜、茯苓、葛根、山药、栗子和大豆,原料除杂,清洗干净,于80-120℃条件下蒸40-60min,蒸熟后在48℃的烘箱中烘干10-12h,再粉碎,过100目筛,得到混合物B;
(3)按重量份取枸杞子、桑葚、核桃仁、芝麻和黑木耳,原料除杂,清洗干净,在48℃的烘箱中烘干4-6h,再粉碎,过100目筛,得到混合物C;
(4)按重量份取海参直接清洗,晾干,粉碎,过100目筛,得到海参粉;
(5)将步骤(1)中的混合物A、步骤(2)中的混合物B、步骤(3)中的混合物C、步骤(4)中的海参粉和奶粉搅拌混匀,再按重量份加入长柄扁桃油和杜仲籽油,继续搅拌,混匀,得到强身健体食品组合物。
本发明另一方面还提供了一种强身健体食品组合物在制备强身健体产品中的应用,所述组合物可制成胶囊剂、片剂、颗粒剂、粉剂等。
本发明各组分功效如下:
酪蛋白磷酸肽:能有效促进人体对钙、铁、锌等二价矿物营养素的吸收和利用,用于补钙和预防改善骨质疏松等。
深海鱼胶原蛋白肽:可促进骨的形成,提高骨强度,具有预防骨质疏松症、关节症、保护胃粘膜、抗溃疡、抗过敏、抑制血压上升、防癌等功效。
牦牛骨粉:富含骨胶原蛋白、骨形成蛋白、软骨素及钙、磷、铁、锌等营养成分,对增强人体骨密度,修复骨密度也有很好的效果,特别是含有防止人体老化的骨胶朊和软骨素,同时含有丰富的锌、铁等微量元素、多种维生素、多种氨基酸等,具有补充机体营养成份和提高免疫力的作用。
海参:含胆固醇低,脂肪含量相对少,营养价值非常高,具有延缓衰老、提高免疫力、增强大脑记忆能力,抗疲劳等功效。
初乳碱性蛋白:分子量小,人体易吸收,可直接作用于骨骼细胞,促进骨骼新陈代谢,能协调成骨细胞和破骨细胞的活动,保持两者的动态平衡,促进骨骼生长,修复骨质,对骨关节炎有很好的效果,能有效提高骨组织主动吸收钙和骨胶原等造骨营养的能力。
水解蛋黄粉:能够增加成骨细胞数量并促进骨骼和牙齿的生成,促进骨骼的钙质沉结,强化骨骼的韧性,抑制破骨细胞的生长,维持骨骼成分的平衡。
磷虾油粉:能够缓解痛风和类风湿关节炎,减少僵硬,肿胀和触痛关节,同时具有延缓衰老,降低胆固醇、预防脑溢血、脑血栓、高血压,健脑益智,预防老年痴呆症等功效。
长柄扁桃油:含有天然抗氧化剂和ω-3脂肪酸有助于人体对矿物质的吸收如钙、磷、锌等,可以促进骨骼生长,另外ω-3脂肪酸有助于保持骨密度,减少因自由基(高活性分子)造成的骨骼疏松。同时,还具有预防心脑血管疾病,抗衰老,美容养颜,改善消化系统功能,促进血液循环,预防癌症等作用。
碳酸钙:用于预防和治疗钙缺乏症,如骨质疏松、手足抽搐症、骨发育不全、佝偻病以及老年人钙、儿童、绝经期妇女等人群钙的补充。
杜仲籽油:杜仲可促进人体骨骼和肌肉中胶原蛋白的合成与分解,有促进代谢、预防骨质疏松的作用,对增强记忆功能、预防血管硬化、镇痛、抗疲劳、抗衰老、抗肿瘤、调节免疫功能等都具有明显效。
白子菜:清热解毒,舒筋接骨,凉血止血。用于支气管肺炎,小儿高热,百日咳,目赤肿痛,风湿关节痛,崩漏;外用治跌打损伤,骨折,外伤出血,乳腺炎,疮疡疔肿,烧烫伤。
茯苓:具有利尿、镇静、抗肿瘤、降血糖、增加心肌收缩力的作用,茯苓多糖有增强免疫功能的作用。
葛根:主治表证发热,项背强痛,麻疹不透,热病口渴,阴虚消渴,热泄热痢,脾虚泄泻。
枸杞子:滋补肝肾,益精明目,用于虚劳精亏,腰膝酸痛,眩晕耳鸣,内热消渴,血虚萎黄,目昏不明,有抗氧化、抗衰老、保肝及抗脂肪肝作用。
桑葚:主入肝肾,善滋阴养血、生津润燥,适于肝肾阴血不足及津亏消渴,肠燥等症,桑椹中的脂肪酸具有分解脂肪、降低血脂,防止血管硬化等作用,还有明目,缓解眼睛疲劳干涩,美容养颜,延缓衰老,防癌抗癌等作用。
核桃仁:具有健脑防老,防止动脉硬化,舒缓疲劳,抑菌消炎,防癌抗癌,补虚强体,提供营养多种功效。
芝麻:有补肝肾,益精血,润肠燥,通乳的功效,可用于治疗身体虚弱、头晕耳鸣、高血压、高血脂、咳嗽、身体虚弱、头发早白、贫血萎黄、津液不足、大便燥结、乳少、尿血等病症。
山药:健脾益胃、助消化,滋肾益精,益肺止咳。山药含有皂苷能够降低胆固醇和甘油三酯,对高血压和高血脂等病症有改善作用,还能延年益寿,增强免疫功能,延缓细胞衰老,抗肝昏迷,减肥健美。
栗子:含有钙、磷、铁、钾等无机盐及丰富的不饱和脂肪酸和维生素、矿物质等,能防治骨质疏松、高血压病、冠心病、动脉硬化等疾病。
大豆:用于脾虚气弱,消瘦少食,贫血、营养不良,湿痹拘挛,水肿、小便不利,寻常疣等。
黑木耳:主治益气不饥等,有补气益智,润肺补脑,降低血压,活血止血之功效,具有促进免疫功能、减轻动脉硬化、延缓衰老、抗辐射抗炎等作用。
与现有技术相比,本发明的有益效果为:
(1)本发明提供的强身健体食品组合物,含有的酪蛋白磷酸肽、初乳碱性蛋白和长柄扁桃油均能够促进人体对钙的吸收利用;在组合物中的加入含钙量丰富的牦牛骨粉、碳酸钙和栗子等以补充钙质;另外,还加入了能够促进骨的形成,增强骨密度,促进骨骼钙质沉结,维持骨骼成分平衡的深海鱼胶原蛋白肽、水解蛋黄粉、磷虾油粉、杜仲籽油、白子菜等,从三个方面来预防和改善骨关节炎症、骨质疏松症等骨骼疾病,取得了显著的效果,无其他副作用。
(2)本发明提供的强身健体食品组合物,通过调整酪蛋白磷酸肽:初乳碱性蛋白的重量比和调整牦牛骨粉:水解蛋黄粉的重量比能够进一步改善人体对钙的吸收能力,明显消除关节炎症,缓解骨关节疼痛。
(3)本发明提供的强身健体食品组合物,选用多种原料,除了能够预防和改善骨关节炎症、骨质疏松症等骨骼疾病,组合物中还加入了茯苓、葛根、枸杞子、桑葚、核桃仁、芝麻、山药、大豆、黑木耳、奶粉、复合维生素和复合矿物质等多种营养物质,经过合理的重量搭配,各种类组分分布均衡,易被人体消化吸收,同时还具有延缓衰老、健脑、预防心血管疾病、增强免疫力、促进新陈代谢等功效。
(4)本发明提供的强身健体食品组合物的制备方法,工艺流程简单,可制成胶囊剂、片剂、颗粒剂、粉剂等口服固体制剂,食用方便,应用面广泛。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.001份、深海鱼胶原蛋白肽3份、牦牛骨粉2份、初乳碱性蛋白1份、水解蛋黄粉0.01份、磷虾油粉0.2份。
具体制备方法如下:
按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉混合均匀,得到强身健体食品组合物。
实施例2一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.3份、深海鱼胶原蛋白肽0.05份、牦牛骨粉0.01份、初乳碱性蛋白0.005份、水解蛋黄粉2份、磷虾油粉0.001份。
利用实施例1的制备方法制备组合物。
实施例3一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.01份、深海鱼胶原蛋白肽2份、牦牛骨粉1份、初乳碱性蛋白0.5份、水解蛋黄粉1份、磷虾油粉0.01份。
利用实施例1的制备方法制备组合物。
实施例4一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.01份、深海鱼胶原蛋白肽2份、牦牛骨粉1份、初乳碱性蛋白0.5份、水解蛋黄粉1份、磷虾油粉0.01份、海参0.01份、长柄扁桃油0.001份、杜仲籽油0.001份、白子菜0.1份、茯苓0.5份、葛根0.1份、枸杞子0.1份。
具体制备方法如下:
(1)按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉混合均匀,得到混合物A;
(2)按重量份取白子菜、茯苓、葛根,原料除杂,清洗干净,于80-120℃条件下蒸40-60min,蒸熟后在48℃的烘箱中烘干10-12h,再粉碎,过100目筛,得到混合物B;
(3)按重量份取枸杞子,原料除杂,清洗干净,在48℃的烘箱中烘干4-6h,再粉碎,过100目筛,得到枸杞子粉;
(4)按重量份取海参直接清洗,晾干,粉碎,过100目筛,得到海参粉;
(5)将步骤(1)中的混合物A、步骤(2)中的混合物B、步骤(3)中的枸杞子粉和步骤(4)中的海参粉搅拌混匀,再按重量份加入长柄扁桃油和杜仲籽油,继续搅拌,混匀,得到强身健体食品组合物。
实施例5一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.01份、深海鱼胶原蛋白肽2份、牦牛骨粉1份、初乳碱性蛋白0.5份、水解蛋黄粉1份、磷虾油粉0.01份、海参0.01份、长柄扁桃油0.001份、杜仲籽油0.001份、白子菜0.1份、茯苓0.5份、葛根0.1份、枸杞子0.1份、桑葚0.05份、核桃仁0.1份、芝麻0.01份、山药0.1份、栗子0.01份、大豆0.5份、黑木耳0.1份。
具体制备方法如下:
(1)按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉和碳酸钙混合均匀,得到混合物A;
(2)按重量份取白子菜、茯苓、葛根、山药、栗子和大豆,原料除杂,清洗干净,于80-120℃条件下蒸40-60min,蒸熟后在48℃的烘箱中烘干10-12h,再粉碎,过100目筛,得到混合物B;
(3)按重量份取枸杞子、桑葚、核桃仁、芝麻和黑木耳,原料除杂,清洗干净,在48℃的烘箱中烘干4-6h,再粉碎,过100目筛,得到混合物C;
(4)按重量份取海参直接清洗,晾干,粉碎,过100目筛,得到海参粉;
(5)将步骤(1)中的混合物A、步骤(2)中的混合物B、步骤(3)中的混合物C、步骤(4)中的海参粉搅拌混匀,再按重量份加入长柄扁桃油和杜仲籽油,继续搅拌,混匀,得到强身健体食品组合物。
实施例6一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.01份、深海鱼胶原蛋白肽2份、牦牛骨粉1份、初乳碱性蛋白0.5份、水解蛋黄粉1份、磷虾油粉0.01份、海参0.01份、长柄扁桃油0.001份、杜仲籽油0.001份、白子菜0.1份、茯苓0.5份、葛根0.1份、枸杞子0.1份、桑葚0.05份、核桃仁0.1份、芝麻0.01份、山药0.1份、栗子0.01份、大豆0.5份、黑木耳0.1份、碳酸钙0.01份、奶粉0.01份。
具体制备方法如下:
(1)按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉和碳酸钙混合均匀,得到混合物A;
(2)按重量份取白子菜、茯苓、葛根、山药、栗子和大豆,原料除杂,清洗干净,于80-120℃条件下蒸40-60min,蒸熟后在48℃的烘箱中烘干10-12h,再粉碎,过100目筛,得到混合物B;
(3)按重量份取枸杞子、桑葚、核桃仁、芝麻和黑木耳,原料除杂,清洗干净,在48℃的烘箱中烘干4-6h,再粉碎,过100目筛,得到混合物C;
(4)按重量份取海参直接清洗,晾干,粉碎,过100目筛,得到海参粉;
(5)将步骤(1)中的混合物A、步骤(2)中的混合物B、步骤(3)中的混合物C、步骤(4)中的海参粉和奶粉搅拌混匀,再按重量份加入长柄扁桃油和杜仲籽油,继续搅拌,混匀,得到强身健体食品组合物。
实施例7一种强身健体食品组合物
其按重量份计包括:酪蛋白磷酸肽0.03份、深海鱼胶原蛋白肽0.6份、牦牛骨粉0.5份、初乳碱性蛋白0.05份、水解蛋黄粉0.5份、磷虾油粉0.02份、海参0.1份、长柄扁桃油0.01份、杜仲籽油0.05份、白子菜1份、茯苓1份、葛根1份、枸杞子1份、桑葚0.6份、核桃仁1份、芝麻0.5份、山药1份、栗子0.5份、大豆1份、黑木耳0.5份、碳酸钙0.2份、奶粉0.6份。
具体制备方法如下:
(1)按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉和碳酸钙混合均匀,得到混合物A;
(2)按重量份取白子菜、茯苓、葛根、山药、栗子和大豆,原料除杂,清洗干净,于80-120℃条件下蒸40-60min,蒸熟后在48℃的烘箱中烘干10-12h,再粉碎,过100目筛,得到混合物B;
(3)按重量份取枸杞子、桑葚、核桃仁、芝麻和黑木耳,原料除杂,清洗干净,在48℃的烘箱中烘干4-6h,再粉碎,过100目筛,得到混合物C;
(4)按重量份取海参直接清洗,晾干,粉碎,过100目筛,得到海参粉;
(5)将步骤(1)中的混合物A、步骤(2)中的混合物B、步骤(3)中的混合物C、步骤(4)中的海参粉和奶粉搅拌混匀,再按重量份加入长柄扁桃油和杜仲籽油,继续搅拌,混匀,得到强身健体食品组合物。
实施例8一种强身健体食品组合物
和实施例7的区别仅在于酪蛋白磷酸肽的重量份为0.005份。
实施例9一种强身健体食品组合物
和实施例7的区别仅在于酪蛋白磷酸肽的重量份为0.05份。
实施例10一种强身健体食品组合物
和实施例7的区别仅在于酪蛋白磷酸肽的重量份为0.25份。
实施例11一种强身健体食品组合物
和实施例7的区别仅在于酪蛋白磷酸肽的重量份为0.5份。
对比例1一种强身健体食品组合物
和实施例1的区别仅在于不含酪蛋白磷酸肽。
对比例2一种强身健体食品组合物
和实施例1的区别仅在于不含牦牛骨粉。
对比例3一种强身健体食品组合物
和实施例1的区别仅在于不含初乳碱性蛋白。
对比例4一种强身健体食品组合物
和实施例1的区别仅在于不含水解蛋黄粉。
对比例5一种改善骨关节炎症的保健食品
中国专利公布CN107252099A实施例1一种改善骨关节炎症的保健食品及其制备方法。
以下研究本发明强身健体食品组合物的增加骨密度功能及食用安全性(依据《保健食品检验与评价技术规范(2003版)》内容进行试验)。
实验例1
将实施例1-11中的食品组合物进行药理实验,实验结果如下:
1.急性毒性试验
样品为:按实施例1-11所述配方用所述的制备方法制备的样品。
试验动物:试验用ICR小鼠。
小鼠经口急性毒性试验(MTD):选用18~22克小鼠110只,每组10只,雌雄各半,进行试验,以20.0g/kg·BW的剂量经口二次灌胃,给药后连续观察14天,记录中毒表现及死亡情况。
结果显示:以20.0g/kg·BW的剂量灌胃两种性别的小鼠,观察14天。试验期间未见明显的中毒表现,观察期内无死亡。受试物对两种性别的小鼠的急性经口毒性(MTD)均大于20.0g/kg·BW,根据《食品安全性毒理学评价程序和方法》(2003年版)急性毒性分级,属无毒级。
2.30天喂养试验
样品:按实施例1-11所述配方用所述的制备方法制备的样品。人拟用剂量为10.0g/60kg·BW·日。
试验动物:选用体重55~80g,SPF级Wistar大鼠340只,雌雄各半。
试验方法:剂量设计为:3.20、8.00、16.00g/kg·BW(分别相当于人拟用剂量的20倍、50倍、100倍)。取10只,雌雄各半,作为对照组,剩下的330只大鼠随机分为11组,每组按照剂量再分为3小组,每小组10只,雌雄各半。对照组喂饲正常基础饲料,试验组则喂饲掺入不同剂量的样品。动物单笼喂养,自由饮食,连续观察30天,每天观察动物的表现、行为、毒性表现和死亡情况。每周称体重1次和两次食物摄入量,计算每周及总的食物利用率。
2.1观察结果显示:各组动物生长发育、活动均正常,无中毒表现和死亡,各组动物每周体重、体重增加量、进食量和食物利用率及总体重增加量、进食量和食物利用率均无统计学差异(p>0.05)。
2.2血液学检查:测定血红蛋白含量(Hgb)、红细胞(RBC)及白细胞(WBC)计数,白细胞分类(淋巴、单核、中性粒、嗜酸、嗜碱)。实验末期血液学的各项指标均在正常值范围内,各组动物血红蛋白、红细胞及白细胞计数、白细胞分类与对照组相比均无统计学差异(p>0.05)。
2.3生化指标测定:测定血清内氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、尿素氮(BUN)、胆固醇(CHO)、甘油三酯(TG)、血糖(GLU)、总蛋白(TP)、白蛋白(ALB)、肌酐(CRE)。实验末期试验动物各项生化指标均在正常值范围内,各组动物学医生化指标与对照组相比均无统计学差异(p>0.05)。
2.4大体观察及病理组织检查:
试验末期颈椎脱臼处死动物,观察各主要脏器及胸、腹腔大体病理改变。取出全部动物的肝脏、肾脏、脾脏、睾丸,称重并计算脏器系数。取出对照组和高剂量组动物的肝脏、肾脏、脾脏、睾丸(或卵巢)、胃及十二指肠,用12%福尔马林固定,石蜡包埋、切片、HE染色,在光镜下进行组织学检查。各主要脏器(心、肝、脾、肺、肾、胃、肠等)均未见有意义的病理改变。
毒理试验结果表明本品对属于无毒级,可以长期服用。
实验例2
增加骨密度功能试验
样品:按实施例1-11和对比例1-5所述配方用所述的制备方法制备的样品。人拟用剂量为10g/60kg·BW·日。
试验动物:4周断乳SD雄性大鼠,体重70-80g,每组10只,用含有胆固醇的饲料喂养动物形成脂代谢紊乱动物模型。
试验方法:试验组的剂量为:10g/60kg·BW·日。对照组喂饲正常基础饲料,给予三个月,观察如下指标,实验项目及结果如下表1-2所示;
表1:对大鼠体重、骨钙的影响
组别 | 实验前体重(g) | 实验后体重(g) | 右股骨重(g) | 骨钙含量(g/kg) |
实施例1 | 77.3±6.12 | 210.6±10.66 | 0.485±0.0309* | 159.82±13.45* |
实施例2 | 79.7±5.83 | 209.4±11.31 | 0.483±0.0294* | 160.64±12.17* |
实施例3 | 77.9±8.14 | 212.6±11.09 | 0.486±0.0326* | 161.40±11.94* |
实施例4 | 76.3±5.45 | 208.4±11.62 | 0.491±0.0381* | 164.81±12.34* |
实施例5 | 77.5±5.21 | 210.8±10.03 | 0.490±0.0315* | 165.11±12.01* |
实施例6 | 77.8±8.02 | 211.4±9.88 | 0.492±0.0294* | 165.66±11.79* |
实施例7 | 79.1±8.37 | 209.2±10.21 | 0.516±0.0408* | 171.85±14.03* |
实施例8 | 76.8±3.18 | 212.1±11.91 | 0.497±0.0331* | 167.33±12.84* |
实施例9 | 78.9±7.89 | 208.9±12.34 | 0.508±0.0436* | 170.63±13.45* |
实施例10 | 76.7±6.20 | 212.1±12.26 | 0.502±0.0370* | 170.32±14.06* |
实施例11 | 79.3±8.21 | 213.5±13.02 | 0.498±0.0447* | 169.81±13.59* |
对比例1 | 78.1±8.62 | 209.1±9.97 | 0.473±0.0504* | 154.42±12.78* |
对比例2 | 75.5±7.29 | 209.6±10.65 | 0.471±0.0351* | 151.97±11.94* |
对比例3 | 76.5±7.74 | 210.5±11.27 | 0.461±0.0246* | 153.86±13.70* |
对比例4 | 78.4±7.25 | 211.4±10.85 | 0.464±0.0336* | 151.07±11.68* |
对比例5 | 77.6±8.33 | 210.8±10.66 | 0.437±0.0251* | 146.71±14.26* |
对照组 | 77.2±5.81 | 208.65±10.53 | 0.314±0.0226 | 125.30±15.91 |
由表1可以看出,实施例1-11和对比例1-5与对照组相比右股骨重和骨钙含量均有显著性差异(P≤0.05),且实施例7的右股骨重和骨钙含量达到最大值。
表2:对大鼠骨密度和骨钙含量的影响
组别 | 中点骨密度 | 远端骨密度 | 骨质最疏松点骨密度 |
实施例1 | 0.16±0.01** | 0.15±0.02** | 0.09±0.02** |
实施例2 | 0.16±0.02** | 0.14±0.02** | 0.09±0.03** |
实施例3 | 0.17±0.01** | 0.14±0.03** | 0.09±0.02** |
实施例4 | 0.17±0.01** | 0.15±0.02** | 0.09±0.02** |
实施例5 | 0.16±0.02** | 0.15±0.03** | 0.10±0.03** |
实施例6 | 0.17±0.02** | 0.15±0.01** | 0.10±0.02** |
实施例7 | 0.19±0.03** | 0.16±0.02** | 0.12±0.03** |
实施例8 | 0.18±0.02** | 0.16±0.01** | 0.11±0.03** |
实施例9 | 0.19±0.03** | 0.16±0.02** | 0.12±0.02** |
实施例10 | 0.19±0.01** | 0.15±0.02** | 0.12±0.01** |
实施例11 | 0.18±0.03** | 0.15±0.03** | 0.12±0.02** |
对比例1 | 0.15±0.03** | 0.14±0.01** | 0.07±0.01** |
对比例2 | 0.15±0.02** | 0.14±0.02** | 0.08±0.01** |
对比例3 | 0.14±0.03** | 0.13±0.02** | 0.07±0.03** |
对比例4 | 0.14±0.02** | 0.12±0.01** | 0.08±0.01** |
对比例5 | 0.11±0.01** | 0.09±0.01** | 0.06±0.02** |
对照组 | 0.05±0.01 | 0.06±0.02 | 0.04±0.01 |
由表2可以看出,实施例1-11和对比例1-5与对照组相比中点骨密度、远端骨密度和骨质最疏松点骨密度均有显著性差异(P≤0.01),且实施例7达到最大值。
实验例3
缓解关节炎症疼痛
选取170名临床上具有骨关节炎病症的患者,实施例1-11和对比例1-5为试验组,1组对照组,每组10人,对照组不服用任何药物,正常饮食,实验组分别服用实施例1-11和对比例1-5制备所得制剂4周。服用前后均进行WOMAC疼痛评分(0~100分,0分代表没有疼痛,100分代表极度疼痛),试验结果见表3:
表3:骨关节炎症WOMAC疼痛评分
组别 | 服用前WOMAC | 服用后WOMAC |
实施例1 | 47.3±12.1 | 31.7±14.3* |
实施例2 | 46.4±13.5 | 31.2±11.7* |
实施例3 | 48.1±14.6 | 32.3±10.8* |
实施例4 | 48.2±12.4 | 31.5±10.6* |
实施例5 | 47.5±10.3 | 31.1±12.4* |
实施例6 | 47.9±11.9 | 30.9±13.7* |
实施例7 | 48.7±16.2 | 27.2±12.3* |
实施例8 | 48.1±12.8 | 28.6±13.9* |
实施例9 | 47.8±11.2 | 27.9±12.7* |
实施例10 | 47.1±11.8 | 28.6±15.4* |
实施例11 | 48.3±14.6 | 29.3±14.5* |
对比例1 | 46.5±11.8 | 32.3±11.9* |
对比例2 | 47.4±12.7 | 32.9±14.2* |
对比例3 | 48.1±11.7 | 33.6±12.5* |
对比例4 | 47.9±14.5 | 33.0±10.7* |
对比例5 | 47.5±11.16 | 35.6±13.20* |
对照组 | 46.2±10.24 | 47.1±10.66 |
由表3可以看出,实施例1-11和对比例1-5与对照组相比服用后WOMAC疼痛评分显著下降,当酪蛋白磷酸肽:初乳碱性蛋白的重量比为0.1:1,0.6:1,1:1,5:1,10:1时,能够达到更佳的缓解骨关节炎症疼痛的效果。
以上所述实施例仅是为充分说明本发明而所举的较佳的实施例,本发明的保护范围不限于此。本技术领域的技术人员在本发明基础上所作的等同替代或变换,均在本发明的保护范围之内。本发明的保护范围以权利要求书为准。
Claims (10)
1.一种强身健体食品组合物,其特征在于:按重量份数计包括:酪蛋白磷酸肽0.001-0.3份、深海鱼胶原蛋白肽0.05-3份、牦牛骨粉0.01-2份、初乳碱性蛋白0.005-1份、水解蛋黄粉0.01-2份、磷虾油粉0.001-0.2份。
2.根据权利要求1所述的强身健体食品组合物,其特征在于:按重量份数计包括:酪蛋白磷酸肽0.01-0.3份、深海鱼胶原蛋白肽0.05-2份、牦牛骨粉0.01-1份、初乳碱性蛋白0.005-0.5份、水解蛋黄粉0.01-1份、磷虾油粉0.01-0.2份。
3.根据权利要求1所述的强身健体食品组合物,其特征在于:按重量份计还包括:海参0.01-1份、长柄扁桃油0.001-1份、杜仲籽油0.001-0.5份、白子菜0.1-3份、茯苓0.5-3份、葛根0.1-3份、枸杞子0.1-2份。
4.根据权利要求1所述的强身健体食品组合物,其特征在于:按重量份计还包括:桑葚0.05-2份、核桃仁0.1-3份、芝麻0.01-2份、山药0.1-2份、栗子0.01-2份、大豆0.5-3份、黑木耳0.1-2份。
5.根据权利要求4所述的强身健体食品组合物,其特征在于:按重量份计还包括:碳酸钙0.01-2份、奶粉0.01-2份。
6.根据权利要求5所述的强身健体食品组合物,其特征在于:按重量份数计包括:酪蛋白磷酸肽0.01-0.3份、深海鱼胶原蛋白肽0.05-2份、牦牛骨粉0.01-1份、初乳碱性蛋白0.005-0.5份、水解蛋黄粉0.01-1份、磷虾油粉0.01-0.2份、海参0.01-1份、长柄扁桃油0.001-0.1份、杜仲籽油0.005-0.1份、白子菜0.1-3份、茯苓0.5-3份、葛根0.1-3份、枸杞子0.1-2份、桑葚0.05-2份、核桃仁0.1-3份、芝麻0.01-2份、山药0.1-2份、栗子0.01-2份、大豆0.5-3份、黑木耳0.1-2份、碳酸钙0.1-2份、奶粉0.05-2份。
7.根据权利要求5所述的强身健体食品组合物,其特征在于:按重量份数计包括:酪蛋白磷酸肽0.01-0.1份、深海鱼胶原蛋白肽0.1-1.5份、牦牛骨粉0.1-1份、初乳碱性蛋白0.01-0.5份、水解蛋黄粉0.1-1份、磷虾油粉0.01-0.1份、海参0.01-0.5份、长柄扁桃油0.005-0.05份、杜仲籽油0.01-0.1份、白子菜0.5-2份、茯苓0.5-2份、葛根0.1-1.5份、枸杞子0.1-1.5份、桑葚0.1-2份、核桃仁0.5-2份、芝麻0.1-1.5份、山药0.5-1.5份、栗子0.1-1.5份、大豆0.5-5份、黑木耳0.1-1.5份、碳酸钙0.1-1份、奶粉0.1-2份。
8.根据权利要求1所述的强身健体食品组合物,其特征在于:
所述的酪蛋白磷酸肽和初乳碱性蛋白的重量比为0.1-10:1;
所述的牦牛骨粉和水解蛋黄粉的重量比为0.01-2:1。
9.根据权利要求6-7任意一项所述的强身健体食品组合物的制备方法,其特征在于,包括以下步骤:
(1)按重量份取酪蛋白磷酸肽、深海鱼胶原蛋白肽、牦牛骨粉、初乳碱性蛋白、水解蛋黄粉、磷虾油粉和碳酸钙混合均匀,得到混合物A;
(2)按重量份取白子菜、茯苓、葛根、山药、栗子和大豆,原料除杂,清洗干净,于80-120℃条件下蒸40-60min,蒸熟后在48℃的烘箱中烘干10-12h,再粉碎,过100目筛,得到混合物B;
(3)按重量份取枸杞子、桑葚、核桃仁、芝麻和黑木耳,原料除杂,清洗干净,在48℃的烘箱中烘干4-6h,再粉碎,过100目筛,得到混合物C;
(4)按重量份取海参直接清洗,晾干,粉碎,过100目筛,得到海参粉;
(5)将步骤(1)中的混合物A、步骤(2)中的混合物B、步骤(3)中的混合物C、步骤(4)中的海参粉和奶粉搅拌混匀,再按重量份加入长柄扁桃油和杜仲籽油,继续搅拌,混匀,得到强身健体食品组合物。
10.由权利要求1-8任意一项所述的强身健体食品组合物制成的胶囊剂、片剂、颗粒剂或粉剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811299271.6A CN109170916A (zh) | 2018-11-02 | 2018-11-02 | 一种强身健体食品组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811299271.6A CN109170916A (zh) | 2018-11-02 | 2018-11-02 | 一种强身健体食品组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109170916A true CN109170916A (zh) | 2019-01-11 |
Family
ID=64941485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811299271.6A Pending CN109170916A (zh) | 2018-11-02 | 2018-11-02 | 一种强身健体食品组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109170916A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111000230A (zh) * | 2019-11-25 | 2020-04-14 | 西安力邦制药有限公司 | 一种促进骨健康的组合物及应用 |
CN112956702A (zh) * | 2021-03-25 | 2021-06-15 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 一种增加骨密度的复合制剂 |
CN115363162A (zh) * | 2022-08-29 | 2022-11-22 | 北京神飞航天应用技术研究院 | 一种宇航级的胶原蛋白肽固体饮品及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101401833A (zh) * | 2008-09-27 | 2009-04-08 | 深圳市一德堂医药有限公司 | 一种预防和/或治疗骨质疏松症的组合物 |
CN102885304A (zh) * | 2012-10-12 | 2013-01-23 | 中科乐仁(北京)科技发展有限公司 | 一种增加骨密度的保健食品组合物及其制备方法 |
CN104839664A (zh) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 骨质疏松医学配方食品 |
CN104855997A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 骨质疏松非全营养配方食品 |
CN104939089A (zh) * | 2015-06-24 | 2015-09-30 | 广州施健生物科技有限公司 | 具有改善骨密度功能的营养组合物及其制备方法与应用 |
CN105639620A (zh) * | 2015-12-29 | 2016-06-08 | 崔俊昌 | 一种增加骨密度的保健食品组合物及其制备方法 |
CN105661509A (zh) * | 2016-01-18 | 2016-06-15 | 烟台新时代健康产业有限公司 | 一种保护骨健康的磷虾油软胶囊及其制备方法和应用 |
CN105770864A (zh) * | 2016-04-08 | 2016-07-20 | 杭州合研科技有限公司 | 一种具有缓解关节炎症疼痛功能的组合物 |
-
2018
- 2018-11-02 CN CN201811299271.6A patent/CN109170916A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101401833A (zh) * | 2008-09-27 | 2009-04-08 | 深圳市一德堂医药有限公司 | 一种预防和/或治疗骨质疏松症的组合物 |
CN102885304A (zh) * | 2012-10-12 | 2013-01-23 | 中科乐仁(北京)科技发展有限公司 | 一种增加骨密度的保健食品组合物及其制备方法 |
CN104839664A (zh) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 骨质疏松医学配方食品 |
CN104855997A (zh) * | 2015-04-23 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 骨质疏松非全营养配方食品 |
CN104939089A (zh) * | 2015-06-24 | 2015-09-30 | 广州施健生物科技有限公司 | 具有改善骨密度功能的营养组合物及其制备方法与应用 |
CN105639620A (zh) * | 2015-12-29 | 2016-06-08 | 崔俊昌 | 一种增加骨密度的保健食品组合物及其制备方法 |
CN105661509A (zh) * | 2016-01-18 | 2016-06-15 | 烟台新时代健康产业有限公司 | 一种保护骨健康的磷虾油软胶囊及其制备方法和应用 |
CN105770864A (zh) * | 2016-04-08 | 2016-07-20 | 杭州合研科技有限公司 | 一种具有缓解关节炎症疼痛功能的组合物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111000230A (zh) * | 2019-11-25 | 2020-04-14 | 西安力邦制药有限公司 | 一种促进骨健康的组合物及应用 |
CN112956702A (zh) * | 2021-03-25 | 2021-06-15 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 一种增加骨密度的复合制剂 |
CN115363162A (zh) * | 2022-08-29 | 2022-11-22 | 北京神飞航天应用技术研究院 | 一种宇航级的胶原蛋白肽固体饮品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103141709B (zh) | 一种鲤鱼饲料及其制备方法 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN110447902B (zh) | 一种具有减肥功效的组合物 | |
CN108719984B (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN102178183A (zh) | 一种五豆综合营养食品 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN105380271A (zh) | 无添加剂全籽粒绿豆复合营养粉及其生产方法 | |
CN109170916A (zh) | 一种强身健体食品组合物及其制备方法 | |
CN1939520A (zh) | 一种可改善记忆的益智胶囊及其制备工艺 | |
CN105918387A (zh) | 一种适用中老年保健食品及制备方法 | |
CN1742927A (zh) | 枸杞桑椹片及其制备工艺 | |
CN103431276A (zh) | 一种供炎性肠病患者食用的五谷杂粮全营养配方食品 | |
CN110742269B (zh) | 一种适合女性产后用的增强记忆力组合物及其制备方法 | |
CN111771970A (zh) | 有助于养胃、护胃的组合物及其制备方法 | |
CN104970220A (zh) | 一种哺乳期母猪配合饲料及其制备方法 | |
KR100278206B1 (ko) | 성장촉진용 건강보조식품 조성물 | |
CN106472684A (zh) | 一种乳制品 | |
CN108935694A (zh) | 一种具有抗疲劳兼补血虚的保健羊奶粉及其制备方法 | |
CN103478549B (zh) | 一种供癫痫患者食用的五谷杂粮全营养配方食品 | |
CN103622090A (zh) | 一种能强肾健体的新型粉糊 | |
CN105995980A (zh) | 一种具有体重管理作用的组合物及其制备方法 | |
CN104888192B (zh) | 一种增加骨密度的海参氨糖制剂及其生产方法 | |
CN107136490A (zh) | 一种肽虫草保健品 | |
CN111227229A (zh) | 一种植物源营养粉及其制备方法和食用方法 | |
CN111528386B (zh) | 一种山楂纳豆固体饮料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |